Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131301 | 0.93 | KCNH2 (0.49) | KCNH2SETD7GAAKDM4EPTAFR | |
| SCHEMBL3132994 | 0.91 | SETD7 (0.45) | KCNH2SETD7GAAKDM4EALDH1A1 | |
| SCHEMBL490196 | 0.86 | SETD7 (0.48) | KCNH2SETD7GAAKDM4EPTAFR | |
| SCHEMBL490195 | 0.82 | SETD7 (0.51) | KCNH2SETD7PTAFRALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL3136931 | 0.80 | SETD7 (0.44) | KCNH2SETD7GAAKDM4EPTAFR | |
| SCHEMBL3134805 | 0.80 | SETD7 (0.47) | KCNH2SETD7GAAKDM4EALDH1A1 | |
| SCHEMBL490434 | 0.79 | OPRD1 (0.48) | KCNH2SETD7PTAFRMEN1MAPT | |
| SCHEMBL490493 | 0.79 | ROCK2 (0.48) | KCNH2SETD7ALDH1A1 | |
| SCHEMBL3138906 | 0.78 | ROCK2 (0.45) | KCNH2SETD7KDM4EALDH1A1RAB9A | |
| SCHEMBL3131643 | 0.75 | KCNH2 (0.56) | KCNH2SETD7PTAFRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067777-B1 | OXEPIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8222419-B2 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100004456-A1 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2067777-A1 | OXEPIN DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004456-A1 | Oxepin derivative | HRH4, HRH3, HCRTR2 | KCNH2 1909/4885SETD7 2087/4885GAA 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.